Galectin Therapeutics Inc (GALT)

Galectin Therapeutics Inc (GALT) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $374M; returns 1 day -5.6%, 1 week -11.9%, 1 year -37.8%.

Galectin Therapeutics Inc. (GALT) is a clinical-stage biotechnology company focused on developing therapies for fibrotic and liver diseases, and cancer. Their primary focus is on belapectin (GR-MD-02), an investigational galectin-3 inhibitor.

Groups GALT belongs to

• Clinical Stage Biotech
• Biotechnology
• Healthcare
• Fibrosis
• Liver Disease
• Clinical Stage
• Life Sciences
• Biopharmaceutical
• Metabolic Disorders

GALT financial model: income statement, cash flow and balance sheet